Retatrutide is Eli Lilly and Company investigational next-generation obesity drug, designed to act on three signals in the body connected to appetite, fullness, blood sugar and energy use: GLP-1, GIP and glucagon
JAMA 320 , 815824 (2018)
Food and Drug Administration (FDA) updated the Ozempic label to include a warning for intestinal blockage after a growing number of post-marketing reports linked GLP-1 receptor agonists to severe gastrointestinal complications
Keywords: carnitine, chronic liver disease, fatigue, frailty, hepatocellular carcinoma, metabolic flexibility, mitochondrial dysfunction, nonalcoholic fatty liver disease INTRODUCTION Carnitine is a trimethylated amino acid composed by lysine and methionine, ubiquitously present in every human cell and has an important role in energy metabolism and production of cellular energy
This hypothesis is further supported by clinical observations that more than 60% of accumulated fatty acids in the liver are derived from the circulation in NAFLD patients 7,8
75-LB: CT-388, A novel once-weekly dual GLP-1 and GIP receptor modulator, is safe, well-tolerated, and produces more than 8% weight loss in four weeks in overweight and obese adults
